National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 – Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments.

Jan 14, 2021

Contributor: J M Gelfand,A W Armstrong,S Bell,G L Anesi,A Blauvelt,C Calabrese,E D Dommasch,S R Feldman,D Gladman,L Kircik,M Lebwohl,V Lo Re,G Martin,J F Merola,J U Scher,S Schwartzman,J R Treat,A S Van Voorhees,C T Ellebrecht,J Fenner,A Ocon,M N Syed,E J Weinstein,G Gondo,S Heydon,S Koons,C T Ritchlin

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 – Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments.

To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.
The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by non-voting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the NPF. A Delphi process was conducted.
The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus, 14 with moderate consensus.
The evidence behind many guidance statements is variable in quality and/or quantity.
These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

Copyright © 2021. Published by Elsevier Inc.

Author

admin

View all posts

About The Expert

J M Gelfand

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: Joel.Gelfand@pennmedicine.upenn.edu.

A W Armstrong

Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

S Bell

National Psoriasis Foundation, Portland OR, USA.

G L Anesi

Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

A Blauvelt

Oregon Medical Research Center, Portland, OR, USA.

C Calabrese

Department of Rheumatology and Immunology, Cleveland Clinic, OH, USA.

E D Dommasch

Department of Dermatology, Harvard Medical School, Boston, MA, USA.

S R Feldman

Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

D Gladman

Krembil Research Institute, Toronto Western Hospital, Ontario, Canada; University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

L Kircik

Department of Dermatology , Icahn School of Medicine at Mount Sinai, New York, NY, USA; Indiana University Medical Center, Indianapolis, IN, USA.

M Lebwohl

Department of Dermatology , Icahn School of Medicine at Mount Sinai, New York, NY, USA.

V Lo Re

Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

G Martin

Dermatology Associates, Maui, HI, USA.

J F Merola

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

J U Scher

Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA.

S Schwartzman

Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA.

J R Treat

Department of Pediatric Dermatology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA.

A S Van Voorhees

Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA.

C T Ellebrecht

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

J Fenner

Department of Dermatology , Icahn School of Medicine at Mount Sinai, New York, NY, USA.

A Ocon

Division of Allergy, Immunology, & Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.

M N Syed

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

E J Weinstein

Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

G Gondo

National Psoriasis Foundation, Portland OR, USA.

S Heydon

National Psoriasis Foundation, Portland OR, USA.

S Koons

National Psoriasis Foundation, Portland OR, USA.

C T Ritchlin

Division of Allergy, Immunology, & Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.

References

PubMed